- Home
- IGIC vs VTYX Comparison
IGIC vs VTYX Comparison
Compare IGIC & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IGIC | VTYX |
|---|---|---|
| Founded | 2001 | 2018 |
| Country | Jordan | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 990.9M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | IGIC | VTYX |
|---|---|---|
| Price | $25.23 | $13.98 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 7 |
| Target Price | ★ $30.33 | $13.50 |
| AVG Volume (30 Days) | 48.9K | ★ 3.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 0.79% | N/A |
| EPS Growth | N/A | ★ 40.30 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $34.82 | N/A |
| Revenue Next Year | $4.01 | N/A |
| P/E Ratio | $9.05 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.82 | $0.90 |
| 52 Week High | $27.63 | $15.34 |
Technical Indicators
Market Signals| Indicator | IGIC | VTYX |
|---|---|---|
| Relative Strength Index (RSI) | 53.72 | 71.25 |
| Support Level | $22.68 | $13.89 |
| Resistance Level | $25.54 | $14.07 |
| Average True Range (ATR) | 0.77 | 0.03 |
| MACD | -0.04 | -0.12 |
| Stochastic Oscillator | 36.09 | 66.67 |
Price Performance
Historical ComparisonAbout IGIC International General Insurance Holdings Ltd.
International General Insurance Holdings Ltd is an international specialist commercial insurer and a reinsurer, underwriting a diverse portfolio of specialty lines. The company operates in a portfolio of Energy, Property, Construction, Engineering, Ports and terminals, Financial Institutions, General Aviation, Professional Indemnity, Casualty, Directors and Officers, Political Violence, Forestry, and Treaty Reinsurance. Its operating segment includes Specialty Longtail; Specialty Short tail and Reinsurance.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.